Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004

The revised guidance is primarily related to the performance of Merck's coxib franchise in overseas markets. A potential fourth quarter U.S. launch of Arcoxia is not included in the guidance.